ImmunityBio, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard Adcock
- Full Time Employees
- 691
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 3530 John Hopkins Court San Diego CA United States 92121
- IPO Date
- Jul 28, 2015
- CIK
- 0001326110
- Website
- immunitybio.com
- Similar Companies
- Business
- ImmunityBio, Inc. (NASDAQ: IBRX) develops next-generation immunotherapies that bolster the natural immune system to fight cancers and infectious diseases; its platforms include antibody-cytokine fusion proteins such as the FDA-approved Anktiva (N-803/nogapendekin alfa inbakicept-pmln), an IL-15 superagonist used in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ; vaccine vectors encompassing DNA, RNA, and adenovirus-based technologies for personalized cancer vaccines and HPV-related therapies; and cell therapies featuring NK-92-derived natural killer cells like PD-L1 t-haNK, alongside T-cell therapies and macrophage activators that target solid tumors (pancreatic, lung, colorectal), liquid tumors, HIV, and Lynch syndrome-associated cancers. The company, founded in 2014 and headquartered in San Diego, California, with additional operations in Culver City, California, and Morrisville, North Carolina, operates as a vertically integrated, commercial-stage biotechnology firm conducting internal cGMP manufacturing and a robust clinical pipeline across multiple phases and indications in collaboration with the National Cancer Institute, Serum Institute of India Private Limited, and BeiGene, Ltd. Recent developments include FDA approval of Anktiva in April 2024, an $80 million equity financing via registered direct offering with institutional investors in July 2025 to support operations and clinical trials, and a partnership with nCartes announced in November 2024 to automate clinical trial data processes.
Company News
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
ImmunityBio Stock Climbs Thursday: What's Going On?
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages
ImmunityBio Stock Jumps: What's Going On?
State Street Corp Grows Holdings in ImmunityBio, Inc. $IBRX
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
Tidal Investments LLC Acquires New Stake in ImmunityBio, Inc. $IBRX
ImmunityBio, Inc. (NASDAQ:IBRX) Receives $14.20 Consensus Target Price from Brokerages
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
ImmunityBio: None Of The Moonshots Is Priced In
Canada Pension Plan Investment Board Acquires Shares of 70,200 ImmunityBio, Inc. $IBRX
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP